Anzeige
Mehr »
Sonntag, 28.09.2025 - Börsentäglich über 12.000 News
Das Paradox-Becken hat sich bewiesen - und American Critical sitzt direkt auf dem nächsten Milliardenfund
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QMBE | ISIN: CA00143Y1034 | Ticker-Symbol: 42FB
Tradegate
26.09.25 | 21:45
0,032 Euro
-10,73 % -0,004
Branche
IT-Dienstleistungen
Aktienmarkt
Sonstige
1-Jahres-Chart
AI/ML INNOVATIONS INC Chart 1 Jahr
5-Tage-Chart
AI/ML INNOVATIONS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,0330,03719:03
0,0000,00026.09.
ACCESS Newswire
621 Leser
Artikel bewerten:
(2)

AI/ML Innovations, Inc.: AIML Hits Key Regulatory Benchmark with 510(k) Filing for MaxYield Signal Enhancement Platform

Proprietary neural network, cloud-based AI-powered technology designed to support clearer ECG signal interpretation across care settings.

TORONTO, ON / ACCESS Newswire / May 15, 2025 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a developer of AI-based signal processing technologies for healthcare, today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its MaxYield?platform.

MaxYield is a cloud-native API and file-processing solution designed to enhance the quality of electrocardiogram (ECG or EKG) signals across 1- to 12-lead configurations in adult patients aged 18 years and older. It applies a proprietary neural network algorithm to reduce noise and improve waveform clarity, with the goal of supporting more consistent ECG signal interpretation in clinical, ambulatory, and wearable monitoring environments.

MaxYield is designed for broad input compatibility, capable of processing data from both hospital-grade systems and mobile devices. The platform is part of AIML's strategy to enable seamless integration of signal optimization capabilities into emerging digital health ecosystems.

This regulatory milestone builds on AIML's prior submission of a Device Master File (MAF) to the FDA. If accepted, the MAF may support future collaborations with manufacturers interested in integrating MaxYield into their own cleared devices, subject to applicable regulatory requirements.

"MaxYield addresses one of the core challenges in digital health-delivering clearer ECG signals in noisy, real-world conditions," said Peter Kendall, President and Chief Commercial Officer of AIML. "This 510(k) submission marks an important step toward helping clinicians access better-quality ECG data in diverse care settings."

MaxYield targets signal distortions commonly seen in mobile, wearable, and dynamic clinical environments-such as motion artifacts, low-amplitude waveforms, baseline wander, and non-physiological noise. By improving signal fidelity, the platform aims to enhance clinician confidence in ECG review and downstream analysis tools.

AIML remains steadfast in its mission to deliver breakthrough solutions at the intersection of artificial intelligence and human health.

Stock Options
The Company also announces a grant of 800,000 stock options ("Options") under the Company's Stock Option Plan ("Plan) to certain directors and consultants of the Company to acquire up to an aggregate of 800,000 common shares in the capital of the Company. The Options were granted effective May 15, 2025 ("Grant Date") and are subject to the terms of the Plan, the applicable grant agreements and the requirements of the Canadian Securities Exchange. The Options were issued at an exercise price of $0.105, vest quarterly over one year and expire five years from the Grant Date.

For more information about AIML:
For detailed information please see AIML's website or the Company's filed documents at www.sedarplus.ca.

Contact:
Blake Fallis
(778) 405-0882
info@aiml-innovations.com

About AIML Innovations Inc.
www.aiml-innovations.com

AIML Innovations Inc. is a global technology company pioneering the use of artificial intelligence and neural networks to transform digital health. Our proprietary platforms leverage advanced signal processing and deep learning to convert complex biometric data into actionable clinical insights-supporting earlier diagnosis, personalized treatment, and more effective care.

With a growing portfolio of regulatory filings, including a 510(k) premarket notification and a registered FDA Device Master File, AIML is committed to rigorous validation and broad interoperability.

AIML's shares trade on the Canadian Securities Exchange (CSE:AIML), the OTCQB Venture Market (AIMLF), and the Frankfurt Stock Exchange (42FB).

On behalf of the Board of Directors:
Paul Duffy, Chairman

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements - Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties, including risks associated with the implementation of the Company's products and services and any future review and/or approval of the Max Yield and/or Device Master File submissions by the FDA as currently proposed or at all. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company, including with respect to the nature and timing of future operations and the receipt of all applicable regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements.

SOURCE: AI/ML Innovations, Inc.



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/aiml-hits-key-regulatory-benchmark-with-510k-filing-for-maxyieldtm-si-1028022

© 2025 ACCESS Newswire
Epische Goldpreisrallye
Der Goldpreis hat ein neues Rekordhoch überschritten. Die Marke von 3.500 US-Dollar ist gefallen, und selbst 4.000 US-Dollar erscheinen nur noch als Zwischenziel.

Die Rallye wird von mehreren Faktoren gleichzeitig getrieben:
  • · massive Käufe durch Noten- und Zentralbanken
  • · Kapitalflucht in sichere Häfen
  • · hohe Nachfrage nach physisch besicherten Gold-ETFs
  • · geopolitische Unsicherheit und Inflationssorgen

Die Aktienkurse vieler Goldproduzenten und Explorer sind in den vergangenen Wochen regelrecht explodiert.

Doch es gibt noch Titel, die Nachholpotenzial besitzen. In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Goldaktien jetzt besonders aussichtsreich sind und warum der Aufwärtstrend noch lange nicht vorbei sein dürfte.

Laden Sie jetzt den Spezialreport kostenlos herunter und profitieren Sie von der historischen Gold-Hausse.

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.